VIR-5818 + pembrolizumab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic HER2-Expressing Cancers
Conditions
Locally Advanced or Metastatic HER2-Expressing Cancers
Trial Timeline
Apr 13, 2022 → Aug 16, 2027
NCT ID
NCT05356741About VIR-5818 + pembrolizumab
VIR-5818 + pembrolizumab is a phase 1/2 stage product being developed by Merck for Locally Advanced or Metastatic HER2-Expressing Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05356741. Target conditions include Locally Advanced or Metastatic HER2-Expressing Cancers.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic HER2-Expressing Cancers were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05356741 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Locally Advanced or Metastatic HER2-Expressing Cancers